Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Entera Bio Announces Collaboration with OPKO Biologics

Wednesday, September 13, 2023

Entera Bio and OPKO Biologics have joined forces in a research collaboration to advance the development of oral peptide tablet formulations designed to address obesity and intestinal malabsorption syndromes.

Under the terms of agreement, OPKO will provide its exclusive long-acting GLP-2 peptide along with specific analogs of Oxyntomodulin (OXM) to be used in the creation of oral tablet formulations, leveraging Entera's specialised oral delivery technology.

This collaboration with OPKO signifies a significant step in expanding the application of oral delivery technology to encompass a wider range of valuable peptides.

It is challenging to administer peptides orally due to their rapid degradation within the gastrointestinal tract and limited permeability. GLP-2 analogs have demonstrated the ability to enhance nutrient absorption in patients afflicted with short bowel syndrome (SBS) and subsequently reduce their reliance on parenteral support. 

The current FDA-approved GLP-2 analog, Teduglutide, necessitates daily subcutaneous injections. In SBS patients, oral drug delivery is especially problematic, as the absorptive capacity of the intestine is diminished due to its shortened length and reduced functionality.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024